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INTRODUCTION
Pneumonia is the leading cause of infectious disease-related deaths in the United States.
1 A prominent pathogen causing pneumonia in both healthcare and community settings is methicillin-resistant Staphylococcus aureus (MRSA). 2 In recent years, rates of communityassociated MRSA pneumonia have been steadily increasing, while MRSA was also becoming a leading cause of healthcare-associated pneumonia, including ventilator-associated pneumonia (VAP). 3, 4 Limited options exist for the treatment of MRSA pneumonia. Vancomycin has been the mainstay of treatment for MRSA infections for years, however rates of treatment failure for pneumonia as high as 40% have been reported. 5 Linezolid is a well-studied alternative to vancomycin that has been available for more than 10 years. Several studies have demonstrated clinical equivalence between the 2 drugs, [6] [7] [8] [9] but some data suggest a significant benefit for linezolid compared with vancomycin for the treatment of pneumonia. [10] [11] [12] Currently, both drugs are recommended as first-line options for the treatment of MRSA pneumonia. 2 In addition to treatment-related factors, host and pathogen characteristics can affect clinical outcomes for patients with MRSA pneumonia. For example, age, underlying comorbidities, severity of illness, multiple lobe involvement, and need for intensive care unit (ICU) admission have been associated with poor clinical outcomes. [9] [10] [11] 13, 14 There are multiple differences among MRSA strains on a molecular level, including staphylococcal cassette chromosome mec (SCCmec) type, presence of the toxin Panton-Valentine leukocidin, and minimum inhibitory concentration, which can affect clinical outcomes. [14] [15] [16] MRSA pneumonia is a complex disease associated with significant morbidity and mortality. Despite the large public health impact of MRSA pneumonia, there are limited published data examining clinical predictors of success or failure. Identification of independent predictors of clinical success could optimize patient care by assisting clinicians in treatment decisions. It was therefore the aim of this study to identify independent predictors of clinical success among a national Veterans Affairs (VA) cohort of MRSA pneumonia patients.
METHODS
The study design and methods were defined a priori in the study protocol, which was reviewed and approved by the Institutional Review Board and Research and Development Committee of the Providence Veterans Affairs Medical Center.
Data Sources
The Veterans Health Administration has utilized an electronic medical record system since 1999. Our study included national standardized databases capturing patient care:
International Classification of Diseases, 9th Revision (ICD-9) diagnostic and procedure codes, pharmacy records for prescriptions, laboratory tests, select laboratory results, mortality, and patient vital signs.
17,18
Patient Population and Study Design 
Independent Predictors
The potential predictors assessed included treatment (linezolid or vancomycin), patient demographics and admission characteristics, comorbidities and medical history, vital signs and laboratory results, previous surgeries and procedures, previous healthcare exposures, and previous medication exposures. 19 To identify comorbidities and medical history, including sitespecific and organism-specific infections in the year before admission, ICD-9 diagnosis and procedure codes from inpatient and outpatient records were utilized. 18 Surgeries, procedures, and radiologic examinations during the admission were identified using ICD-9 diagnosis and procedure codes. Hospital admissions, surgeries, and nursing home or extended-care stays were evaluated from 5 non-mutually exclusive time periods (30 days, 60 days, 90 days, 180 days, 365 days) to identify previous healthcare exposures. Previous antibiotic and immunosuppressant exposures during the 90 days before admission were identified from inpatient and outpatient prescription records.
Statistical Analysis
Between-group differences were assessed using a χ 2 or Fisher's exact test for categorical covariates and the t-test or Wilcoxon rank-sum test for continuous variables, as
appropriate. An unconditional logistic regression model was developed to identify independent predictors associated with clinical success using a manual backward, non-computer-generated, elimination approach. 20 We report unadjusted and multivariable adjusted odds ratios (ORs) for each predictor, including their respective 95% confidence intervals (CIs). All analyses were performed using SAS (SAS Institute Inc., Cary, NC, Version 9.1.3).
RESULTS
Our study included 2442 cases of clinical success and 1290 non-success controls. There were significant differences in demographics between the clinical success and non-success groups, including age and race (Table I) . Patients in the clinical success group were older than patients in the non-success group (mean age 69.5 ± 12.6 years vs 68.5 ± 12.0 years, P < 0.05). White patients made up a larger proportion of the clinical success group than the non-success group (81.7% vs 79.1%, P < 0.05). Several significant differences in comorbidities were also observed between groups, including less frequent peripheral vascular disease, coagulopathy, and dialysis and more frequent chronic respiratory disease among patients experiencing clinical success. In addition, patients with clinical success were less likely to have an intravenous line or current complication of an implant or graft and were less likely to be in a surgical unit at treatment initiation.
Treatment with linezolid was more common in the clinical success group (6.8% vs 5.0%, P < 0.05), as shown in Table II [32] [33] [34] Our study further adds to this developing literature by assessing a large national cohort of patient with MRSA pneumonia using objective clinical outcomes.
It is unclear why a previous complication of an implant or graft was associated with clinical success in our study. Complications included a range of conditions, such as mechanical complications, infections, or other non-specified complications of medical devices, implants, or grafts. 18 One possible explanation is that this specific medical history could have prompted more aggressive measures to improve the likelihood of clinical success. If this were the case, our findings suggest that MRSA pneumonia patients with previous endocarditis, coagulopathy, and amputation procedures in the year prior to admission may also benefit from additional efforts to improve clinical success.
There are multiple limitations to our study. First, it should be noted that our definition of clinical success varies from those of the aforementioned clinical trials, which affects our ability to make direct comparisons. However, our definition was determined by objective criteria of clinical outcomes rather than clinical judgment as used in those trials. Other limitations include our retrospective design and use of diagnosis codes to identify MRSA pneumonia. There may be variations in coding practices across institutions, and the MRSA coding can be discordant with culture-confirmed MRSA. 35 Furthermore, we were unable to molecularly classify the MRSA isolates; molecular differences in MRSA strains have been shown to affect clinical results. [14] [15] [16] Susceptibility data and trough data were not available, and therefore it is not known if subjects reached therapeutic levels of the treatment agent.
In summary, clinical success in our study was 53% higher among MRSA pneumonia 
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